Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioArctic AB's Enterprise Value is kr27,463 Mil.
BioArctic AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was kr438 Mil. Therefore, BioArctic AB's EV-to-EBIT ratio for today is 62.71.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, BioArctic AB's Enterprise Value is kr27,463 Mil.
BioArctic AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr438 Mil. Therefore, BioArctic AB's EV-to-EBITDA ratio for today is 62.71.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, BioArctic AB's Enterprise Value is kr27,463 Mil.
BioArctic AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr1,147 Mil. Therefore, BioArctic AB's EV-to-Revenue ratio for today is 23.94.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, BioArctic AB's Enterprise Value is kr27,463 Mil.
BioArctic AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr1,253 Mil. Therefore, BioArctic AB's EV-to-FCF ratio for today is 21.91.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
BioArctic AB (LTS:0RV2) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
BioArctic AB's current Enterprise Value is kr27,463 Mil.
BioArctic AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr438 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
BioArctic AB's current Enterprise Value is kr27,463 Mil.
BioArctic AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr438 Mil.
BioArctic AB's current Enterprise Value is kr27,463 Mil.
BioArctic AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,147 Mil.
BioArctic AB's current Enterprise Value is kr27,463 Mil.
BioArctic AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,253 Mil.
BioArctic AB's current Enterprise Value is kr27,463 Mil.
BioArctic AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,253 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioArctic AB Enterprise Value Related Terms
BioArctic AB Enterprise Value Historical Data
* Premium members only.
The historical data trend for BioArctic AB's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RV2 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, BioArctic AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioArctic AB Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioArctic AB's Enterprise Value distribution charts can be found below:
* The bar in red indicates where BioArctic AB's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
BioArctic AB's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of kr27,463 Mil mean?
BioArctic AB (LTS:0RV2) has a Enterprise Value of kr27,463 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on BioArctic AB and its competitors.
Is BioArctic AB's Enterprise Value too high?
BioArctic AB's current Enterprise Value is kr27,463 Mil. Overall, BioArctic AB has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's Enterprise Value compare to VRTX and REGN?
BioArctic AB's Enterprise Value of kr27,463 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on BioArctic AB and its competitors. BioArctic AB's current Enterprise Value is kr27,463 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (LTS:0RV2) is currently considered Significantly Undervalued. The stock's GF Value™ is kr481.99, compared to a current price of kr331.50 — trading 31.2% below its estimated fair value. The current Enterprise Value is kr27,463 Mil. BioArctic AB's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For BioArctic AB (LTS:0RV2), the current Enterprise Value is kr27,463 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioArctic AB (LTS:0RV2) Overvalued in 2026?
Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued.
The current stock price of kr331.50 is trading 31.2% below its estimated GF Value™ of kr481.99.
GuruFocus considers BioArctic AB to be Significantly Undervalued.
Key valuation signals for LTS:0RV2:
Enterprise Value: kr27,463 Mil
GF Value™: kr481.99 vs. price of kr331.50 (31.2% below fair value)
No single metric tells the full story. See the LTS:0RV2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
76GF Score
Get the complete analysis for LTS:0RV2
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RV2 has been successfully added to your 
